External validation of the DIAFORA system to predict lower-extremity amputations in a prospective Danish cohort

IF 3.2 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Johan Røikjer, Matilde Monteiro-Soares, Daina Walton, Elisabetta Iacopi, Jarmila Jirkovska, Michael Edmonds, Anna Trocha, William Jeffocate, Sicco Bus, the Diabetic Foot Study Group (DFSG) prevention of the first ulcer research group
{"title":"External validation of the DIAFORA system to predict lower-extremity amputations in a prospective Danish cohort","authors":"Johan Røikjer,&nbsp;Matilde Monteiro-Soares,&nbsp;Daina Walton,&nbsp;Elisabetta Iacopi,&nbsp;Jarmila Jirkovska,&nbsp;Michael Edmonds,&nbsp;Anna Trocha,&nbsp;William Jeffocate,&nbsp;Sicco Bus,&nbsp;the Diabetic Foot Study Group (DFSG) prevention of the first ulcer research group","doi":"10.1111/dme.15443","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>A diabetes-related foot ulcer (DFU) is a major risk factor for lower-extremity amputation (LEA). To help clinicians predict the risk of LEA in people with DFU, the Diabetic Foot Risk Assessment (DIAFORA) system was developed but has never been externally validated.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In this study, 317 people presenting with a new DFU were included. At baseline, participants were grouped into three groups based on their DIAFORA score: low-risk (&lt;15), medium-risk (15–25), and high-risk (&gt;25). Participants were followed until healing, LEA, death, or at least 3 months. Discriminative accuracy was evaluated using sensitivity, specificity, likelihood ratios (LRs) and the area under the curve (AUC).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>All 317 participants completed at least 3 months of follow-up for a median duration of 146 days, during which 12.6% underwent minor amputation and 2.5% major amputation. People in the low- and medium-risk categories had major amputation rates of 0.9% and 2.1%, respectively, and negative LR of major LEA of 0.10 and 0.38, respectively, while the people in the high-risk category had an amputation rate of 25.0% and a positive LR of 12.9. The DIAFORA risk groups had a sensitivity of 75.0% and a specificity of 65.7%, with a corresponding AUC of 0.78 (95% CI 0.68–0.87) for the prediction of major LEA.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The DIAFORA score is a useful tool for risk stratification of people presenting with a newly occurred DFU, with the external validation presenting results similar to those presented in the original study. The DIAFORA score may guide clinicians towards more individualized DFU treatment regimens.</p>\n </section>\n </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":"42 1","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635586/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetic Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dme.15443","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aim

A diabetes-related foot ulcer (DFU) is a major risk factor for lower-extremity amputation (LEA). To help clinicians predict the risk of LEA in people with DFU, the Diabetic Foot Risk Assessment (DIAFORA) system was developed but has never been externally validated.

Methods

In this study, 317 people presenting with a new DFU were included. At baseline, participants were grouped into three groups based on their DIAFORA score: low-risk (<15), medium-risk (15–25), and high-risk (>25). Participants were followed until healing, LEA, death, or at least 3 months. Discriminative accuracy was evaluated using sensitivity, specificity, likelihood ratios (LRs) and the area under the curve (AUC).

Results

All 317 participants completed at least 3 months of follow-up for a median duration of 146 days, during which 12.6% underwent minor amputation and 2.5% major amputation. People in the low- and medium-risk categories had major amputation rates of 0.9% and 2.1%, respectively, and negative LR of major LEA of 0.10 and 0.38, respectively, while the people in the high-risk category had an amputation rate of 25.0% and a positive LR of 12.9. The DIAFORA risk groups had a sensitivity of 75.0% and a specificity of 65.7%, with a corresponding AUC of 0.78 (95% CI 0.68–0.87) for the prediction of major LEA.

Conclusion

The DIAFORA score is a useful tool for risk stratification of people presenting with a newly occurred DFU, with the external validation presenting results similar to those presented in the original study. The DIAFORA score may guide clinicians towards more individualized DFU treatment regimens.

Abstract Image

DIAFORA 系统在丹麦前瞻性队列中预测下肢截肢情况的外部验证。
目的:糖尿病足溃疡(DFU)是下肢截肢(LEA)的主要风险因素。为了帮助临床医生预测 DFU 患者的 LEA 风险,我们开发了糖尿病足风险评估系统 (DIAFORA),但该系统从未经过外部验证:本研究共纳入 317 名新发 DFU 患者。基线时,根据参与者的 DIAFORA 评分将其分为三组:低风险组(25 分)。对参与者进行随访,直至痊愈、LEA、死亡或至少 3 个月。使用灵敏度、特异性、似然比(LRs)和曲线下面积(AUC)对判别准确性进行评估:所有317名参与者都完成了至少3个月的随访,中位随访时间为146天,其间12.6%的人接受了轻微截肢手术,2.5%的人接受了大截肢手术。低风险和中风险人群的大截肢率分别为 0.9% 和 2.1%,大截肢率的负 LR 分别为 0.10 和 0.38,而高风险人群的截肢率为 25.0%,正 LR 为 12.9。DIAFORA 风险组预测重大 LEA 的灵敏度为 75.0%,特异度为 65.7%,相应的 AUC 为 0.78(95% CI 0.68-0.87):结论:DIAFORA评分是对新发DFU患者进行风险分层的有用工具,其外部验证结果与原始研究结果相似。DIAFORA 评分可指导临床医生制定更加个性化的 DFU 治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetic Medicine
Diabetic Medicine 医学-内分泌学与代谢
CiteScore
7.20
自引率
5.70%
发文量
229
审稿时长
3-6 weeks
期刊介绍: Diabetic Medicine, the official journal of Diabetes UK, is published monthly simultaneously, in print and online editions. The journal publishes a range of key information on all clinical aspects of diabetes mellitus, ranging from human genetic studies through clinical physiology and trials to diabetes epidemiology. We do not publish original animal or cell culture studies unless they are part of a study of clinical diabetes involving humans. Categories of publication include research articles, reviews, editorials, commentaries, and correspondence. All material is peer-reviewed. We aim to disseminate knowledge about diabetes research with the goal of improving the management of people with diabetes. The journal therefore seeks to provide a forum for the exchange of ideas between clinicians and researchers worldwide. Topics covered are of importance to all healthcare professionals working with people with diabetes, whether in primary care or specialist services. Surplus generated from the sale of Diabetic Medicine is used by Diabetes UK to know diabetes better and fight diabetes more effectively on behalf of all people affected by and at risk of diabetes as well as their families and carers.”
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信